Grants and Contributions:
Title:
Development of Novel Quinazoline-Based EGFR Inhibitors as Cancer Therapeutics
Agreement Number:
1032220
Agreement Value:
$50,400.00
Agreement Date:
Jul 1, 2025 - Mar 31, 2026
Description:
Firm would like to design and develop novel EGFR (epidermal growth factor receptor) inhibitor cancer therapeutic that improve selectivity to allow irreversible inhibition to overcome resistance mutations. EGFR plays a central role in cell proliferation and survival. Aberrant EGFR signaling is a driver mutation in many tumors, making it an ideal and validated target for cancer therapy. Despite many pharmaceutical companies actively advancing EGFR inhibitors, drug resistance and severe side effects remain unsolved challenges that need to be addressed.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Edmonton, Alberta, CA T6E 5P8
Reference Number:
172-2025-2026-Q2-1032220
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
835357500
Recipient Type:
For-profit organization
Recipient's Legal Name:
Alberta Research Chemicals Inc.
Federal Riding Name:
Edmonton Mill Woods
Federal Riding Number:
48017
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710